Adimmune Corporation (TWSE: 4142) today announced the Company has been awarded the advanced purchase agreement (APA) for pandemic influenza vaccine by Taiwan Centers for Disease Control (CDC), Ministry of Health and Welfare. This APA ensures Taiwan’s swift access to vaccines in the event of a new influenza pandemic. As the only vaccine manufacturer in Taiwan participating in the Influenza Vaccine Supply (IVS) International Task Force of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Adimmune is uniquely positioned to obtain new influenza virus strains promptly. 

Under the terms of “2023-2025 Pandemic Influenza Vaccine Advanced Purchase Agreement”, Adimmune will undertake the selection of potential influenza strains, develop new pandemic influenza vaccines, and enhance production, manufacturing, and processes. The scope of work also includes clinical trial planning and marketing authorization applications. To ensure a prompt and consistent vaccine supply to the Taiwanese public in the event of a new influenza pandemic, Adimmune will provide regular progress reports. The contract value is TWD 72,000,000. 

Adimmune has been dedicated to research and development for pandemic influenza vaccines. Currently, our annual production of quadrivalent influenza vaccines contain four influenza viruses (two influenza A and two influenza B viruses in accordance with WHO recommendation for the year), while pandemic influenza vaccines contain only a single strain of influenza virus. According to the CDC, pandemic influenza refers to the influenza viruses mainly found in animals, such as birds or swine, and once they mutate, they can potentially infect humans. The WHO has been closely monitoring novel influenza A viruses that may be circulating globally, including H5, H7, and H9, among others.  

“Adimmune is committed to internationalization and has joined the IVS of the IFPMA as early as 2012,” said Chin-Chuan Chang, Chief Operating Officer of Adimmune. “Adimmune is also an IFPMA member along with Sanofi, GSK, and 17 other leading influenza vaccine suppliers in the world. Members can participate in the WHO seasonal influenza vaccine virus selection meetings (at end of February for the northern hemisphere and end of September for the southern hemisphere) to gain the access to influenza virus stains and the latest global influenza surveillance data promptly. Additionally, it provides a platform for exchanging insights and information with other major international vaccine manufacturers.

” Adimmune is also a partner of the WHO’s PIP (Pandemic Influenza Preparedness) Framework. Adimmune, Taiwan’s only influenza vaccine manufacturer participating in the PIP, possesses a unique advantage in responding swiftly and effectively to new influenza outbreaks and vaccine production. As long as a new strain of influenza virus is obtained and the clinical and regulatory requirements are satisfied, Adimmune is capable of addressing the needs of the public in Taiwan within six months. 

Adimmune’s quadrivalent influenza vaccine not only supplies more than 50% of Taiwan’s public tender influenza vaccines every year, but also serves the Thailand and China markets. This year, the Company is actively applying for marketing authorizations to expand the Asian market. In addition, Adimmune has been working with potential partners for the influenza vaccine market in the southern hemisphere. 

 “As a local vaccine manufacturer, Adimmune is firmly committed to epidemic prevention in Taiwan. In times of crisis, Adimmune will definitely supplies vaccines essential for the Taiwanese people. We are dedicated to fulfilling our social responsibility and remain fully engaged in localized production and global market expansion. These lessons have been reinforced by our experiences during the COVID-19 pandemic,” said Chi-Hsien Chan, the Chairman & CEO of Adimmune.